Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 23 June, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Procter & Gamble Health Ltd

Basic Stock Data

Last Updated: June 19, 2024, 2:27 pm

Market Cap 8,275 Cr.
Current Price 4,985
High / Low5,643/4,637
Stock P/E38.6
Book Value 485
Dividend Yield1.87 %
ROCE45.5 %
ROE33.5 %
Face Value 10.0
PEG Ratio-11.44

Competitors of Procter & Gamble Health Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Biocon Ltd 40,196 Cr. 335349/21839.0 1650.15 %6.12 %5.47 % 5.00
Syncom Formulations (India) Ltd 1,189 Cr. 12.618.6/7.0950.3 3.050.00 %10.4 %8.72 % 1.00
Suven Life Sciences Ltd 2,209 Cr. 101129/58.5 12.40.00 %35.0 %34.9 % 1.00
Cian Healthcare Ltd 60.8 Cr. 24.327.8/16.0243 23.10.00 %4.94 %0.43 % 10.0
Cipla Ltd 1,24,472 Cr. 1,5421,582/98929.2 3310.55 %23.1 %17.0 % 2.00
Industry Average15,327.12 Cr1,163.8738.33192.600.34%16.99%16.51%6.46

Quarterly Result

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Sales219285273278268296298310321301305310252
Expenses188237195216199237207201241256216208185
Operating Profit3148786269599110980458910267
OPM %14%17%29%22%26%20%31%35%25%15%29%33%27%
Other Income3235233555652
Interest0000000000000
Depreciation8777677866677
Profit before tax2644746065558710579448810063
Tax %40%22%25%25%21%25%26%27%25%32%26%28%26%
Net Profit16345545514164775930667247
EPS in Rs9.5020.4233.3627.0130.8224.8138.3546.2735.6617.9639.5043.4228.05

Last Updated: June 9, 2024, 12:25 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 26, 2024, 8:47 pm

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023TTM
Sales6877988679409936988499271,3561,0091,1141,2301,169
Expenses5827218098558776217017231,037762846905865
Operating Profit10677598511677148204319246268325303
OPM %15%10%7%9%12%11%17%22%24%24%24%26%26%
Other Income202120222474768486618131819
Interest0000000001011
Depreciation9101323251921172930272827
Profit before tax117886783115132895234355233253314295
Tax %33%37%35%36%31%29%6%32%28%24%24%27%
Net Profit785643547994839159254177193229214
EPS in Rs47.2333.6626.0432.2747.6756.57505.2795.64153.07106.51115.98138.24128.93
Dividend Payout %5%25%23%23%23%27%87%0%150%122%45%44%

Profit & Loss Yearly Chart

Unable to calculate Year-wise YoY Net Profit Growth.

Growth

Compounded Sales Growth
10 Years:6%
5 Years:12%
3 Years:-3%
TTM:-5%
Compounded Profit Growth
10 Years:11%
5 Years:23%
3 Years:-4%
TTM:-11%
Stock Price CAGR
10 Years:22%
5 Years:6%
3 Years:-8%
1 Year:3%
Return on Equity
10 Years:27%
5 Years:37%
3 Years:28%
Last Year:33%

Last Updated: May 2, 2024, 11:23 am

Balance Sheet

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023Dec 2023
Equity Capital17171717171717171717171717
Reserves4675065385756477171,524800890687600734789
Borrowings000000000831211
Other Liabilities111125154192215258219250269275269338260
Total Liabilities5946487087848799911,7591,0671,1769868881,1011,077
Fixed Assets7585110132111115104101101104112144143
CWIP2928730917112139413228
Investments2424244228700000000
Other Assets4945305476037117971,6399541,053843736925906
Total Assets5946487087848799911,7591,0671,1769868881,1011,077

Reserves and Borrowings Chart

Procter & Gamble Health Ltd Cash Flow

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023
Cash from Operating Activity 54058310754-130235247170236
Cash from Investing Activity -82711-68-75-481,270165-32-26-22
Cash from Financing Activity 0-5-17-12-15-22-30-883-387-289-98
Net Cash Flow-283-1417-161,109-483-172-145116

Free Cash Flow

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023
Free Cash Flow106.0077.0059.0085.00116.0077.00148.00204.00319.00238.00265.00313.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Jun 2020Jun 2021Jun 2022Jun 2023
Debtor Days343844493964283026222734
Inventory Days160153162140145243154139113138124136
Days Payable4837405567128124106105209185239
Cash Conversion Cycle146154166134118179586334-49-34-69
Working Capital Days77707469529442222391816
ROCE %26%18%12%15%18%16%78%29%29%38%45%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%
FIIs6.45%5.88%5.97%6.57%6.47%6.05%6.33%6.72%7.15%7.38%7.60%6.24%
DIIs11.81%8.36%8.53%7.91%8.07%12.62%12.44%12.31%12.29%12.30%12.66%13.72%
Public29.93%33.94%33.69%33.71%33.64%29.51%29.41%29.14%28.74%28.50%27.92%28.22%
No. of Shareholders58,81863,52565,53766,28965,72965,14863,83161,03058,85657,91956,73056,778

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund596,8070.75306.113,6712024-06-174265.5%
HDFC Small Cap Fund - Regular Plan326,8340.66167.6313,6712024-06-172290.71%
DSP Healthcare Fund158,7044.2381.413,6712024-06-171060.88%
UTI MNC Fund145,8872.8374.8213,6712024-06-17967.13%
Sundaram Small Cap Fund74,5541.3338.2413,6712024-06-17445.34%
UTI Healthcare Fund35,0002.117.9513,6712024-06-17156.02%
Tata Retirement Savings Fund - Moderate Plan - Regular Plan31,0000.8615.913,6712024-06-17126.76%
Tata Retirement Savings Fund - Progressive Plan - Regular Plan28,8000.9114.7713,6712024-06-17110.66%
Tata India Pharma & HealthCare Fund16,0001.098.2113,6712024-06-1717.04%
Aditya Birla Sun Life MNC Fund - Div13,6710.27.0113,6712024-06-170%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthJun 23Jun 22Jun 21Jun 20Dec 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)138.00116.00107.00153.0095.64
Diluted EPS (Rs.)138.00116.00107.00153.0095.64
Cash EPS (Rs.)155.16132.29124.60170.80105.98
Book Value[Excl.RevalReserv]/Share (Rs.)452.34371.38423.92545.99492.09
Book Value[Incl.RevalReserv]/Share (Rs.)452.34371.38423.92545.99492.09
Dividend / Share (Rs.)95.0052.50130.00230.00230.00
Revenue From Operations / Share (Rs.)740.73671.33607.67816.78558.23
PBDIT / Share (Rs.)206.67169.20159.11231.51151.53
PBIT / Share (Rs.)189.74152.88141.01213.76141.19
PBT / Share (Rs.)189.28152.63140.53213.76141.19
Net Profit / Share (Rs.)138.23115.97106.51153.0695.64
PBDIT Margin (%)27.9025.2026.1828.3427.14
PBIT Margin (%)25.6122.7723.2026.1725.29
PBT Margin (%)25.5522.7323.1226.1725.29
Net Profit Margin (%)18.6617.2717.5218.7317.13
Return on Networth / Equity (%)30.5531.2225.1228.0319.43
Return on Capital Employeed (%)39.5038.5731.3237.4127.76
Return On Assets (%)20.8321.5417.9221.6114.88
Asset Turnover Ratio (%)1.231.190.930.0086.86
Current Ratio (X)2.622.603.044.213.80
Quick Ratio (X)2.182.112.553.623.29
Inventory Turnover Ratio (X)2.552.772.290.008.11
Dividend Payout Ratio (NP) (%)40.87147.43215.93287.450.00
Dividend Payout Ratio (CP) (%)36.41129.25184.57257.590.00
Earning Retention Ratio (%)59.13-47.43-115.93-187.450.00
Cash Earning Retention Ratio (%)63.59-29.25-84.57-157.590.00
Interest Coverage Ratio (X)445.55668.74330.150.000.00
Interest Coverage Ratio (Post Tax) (X)299.01459.38222.000.000.00
Enterprise Value (Cr.)8273.456626.398817.136112.466656.85
EV / Net Operating Revenue (X)6.735.958.744.517.18
EV / EBITDA (X)24.1223.5933.3815.9126.47
MarketCap / Net Operating Revenue (X)7.096.249.214.987.80
Retention Ratios (%)59.12-47.43-115.93-187.450.00
Price / BV (X)11.6011.2813.207.458.84
Price / Net Operating Revenue (X)7.096.249.214.987.80
EarningsYield0.020.020.010.030.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: 6,388.81

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 28.16% compared to the current price 4985

Intrinsic Value: 6,173.24

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 23.84% compared to the current price ₹4985

Last 5 Year EPS CAGR: -3.37%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 27.00%, which is a positive sign.
  2. The company has higher reserves (728.77 cr) compared to borrowings (2.62 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (520.31 cr) and profit (244.69 cr) over the years.
  1. The stock has a high average Working Capital Days of 47.17, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 75.00, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Procter & Gamble Health Ltd:
    1. Net Profit Margin: 18.66%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 39.50% (Industry Average ROCE: %)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 30.55% (Industry Average ROE: %)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 299.01
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.18
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✗ Stock P/E: 38.6 (Industry average Stock P/E: )
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✗ Total Debt / Equity: N/A
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company

Procter & Gamble Health Ltd. is a Public Limited Listed company incorporated on 26/04/1967 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L99999MH1967PLC013726 and registration number is 013726. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 1114.41 Cr. and Equity Capital is Rs. 16.60 Cr. for the Year ended 30/06/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsP&G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400099investorgrievance.im@pg.com
https://www.pghealthindia.com
Management
NamePosition Held
Mr. Suresh TalwarChairman & Ind.Director
Mr. Milind ThatteManaging Director
Mr. Lokesh ChandakExecutive Director & CFO
Ms. Seema SambasivanNon Executive Director
Mr. Aalok AgrawalNon Executive Director
Mrs. Rani JadhavIndependent Director
Mr. S MadhavanIndependent Director

FAQ

What is the latest fair value of Procter & Gamble Health Ltd?

The latest fair value of Procter & Gamble Health Ltd is ₹6388.81.

What is the Market Cap of Procter & Gamble Health Ltd?

The Market Cap of Procter & Gamble Health Ltd is 8,275 Cr..

What is the current Stock Price of Procter & Gamble Health Ltd as on 23 June 2024?

The current stock price of Procter & Gamble Health Ltd as on 23 June 2024 is ₹4,985.

What is the High / Low of Procter & Gamble Health Ltd stocks in FY 2024?

In FY 2024, the High / Low of Procter & Gamble Health Ltd stocks is 5,643/4,637.

What is the Stock P/E of Procter & Gamble Health Ltd?

The Stock P/E of Procter & Gamble Health Ltd is 38.6.

What is the Book Value of Procter & Gamble Health Ltd?

The Book Value of Procter & Gamble Health Ltd is 485.

What is the Dividend Yield of Procter & Gamble Health Ltd?

The Dividend Yield of Procter & Gamble Health Ltd is 1.87 %.

What is the ROCE of Procter & Gamble Health Ltd?

The ROCE of Procter & Gamble Health Ltd is 45.5 %.

What is the ROE of Procter & Gamble Health Ltd?

The ROE of Procter & Gamble Health Ltd is 33.5 %.

What is the Face Value of Procter & Gamble Health Ltd?

The Face Value of Procter & Gamble Health Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Procter & Gamble Health Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE